Alzprotect
PrivateLast Round
Grant
Jun 1, 2022
Total Funding Raised
$26.29M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Alzprotect operates in Healthcare & Life Sciences and is based in Lille. Its latest recorded funding round was a Grant round in June 2022.
Alzprotect is a biopharmaceutical company that develops drug candidates for the treatment of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and Progressive Supranuclear Palsy.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Alzprotect Comparables
Compare Alzprotect with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Asceneuron | 85% | |
| Transposon Therapeutics | 79% | |
| Oligomerix, Inc. | 78% |
For institutional investors. Book with your work email.
Alzprotect Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jun 1, 2022 | ||||
| Corporate Funding | Jan 1, 2022 | ||||
| Series B | Jan 23, 2018 | ||||
| Series A Extension | Sep 21, 2016 | ||||
| Debt | Jun 11, 2014 | ||||
Series A | Jun 11, 2014 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Alzprotect Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Xerys | Corporate Funding, Series B |
| Invest Securities | Series A Extension |
| Finorpa | Seed |
| Siparex Group | Corporate Funding, Seed, Series A, Series A Extension |
| The Michael J. Fox Foundation for Parkinson's Research | Grant |
| Finovam Gestion | Corporate Funding, Series A, Series A Extension |
| Bpifrance | Debt |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 64% MoM, reaching 1.2K.
- May 1, 2025
Monthly visitors increased 744% MoM, from 59 to 498.
For institutional investors. Book with your work email.
Alzprotect Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Alzprotect's valuation, stock price, and market status.
Is Alzprotect a public or private company?
Alzprotect is a private company.
What is the current stock price of Alzprotect?
Alzprotect is a private company, so its shares have no public market price. Caplight tracks Alzprotect's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Alzprotect worth (valuation)?
Valuation information for Alzprotect is not publicly available.
Can I buy Alzprotect stock?
Alzprotect shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Alzprotect's last funding round?
Alzprotect's most recent funding round was Grant on June 1, 2022.
Who are the main investors in Alzprotect?
Key investors in Alzprotect include Xerys, Bpifrance.
Will Alzprotect IPO soon?
No public IPO plans have been announced for Alzprotect.
How can I track Alzprotect secondary market activity?
Caplight tracks bids, offers, and trades in Alzprotect's shares on secondary markets.